Table 2.
Baseline Clinical Characteristics of Patients With Myelofibrosis Receiving Lenalidomide and Prednisone
| Characteristic | No. | % |
|---|---|---|
| Median age, years | 62 | |
| Range | 41-86 | |
| Median time from diagnosis, months | 10 | |
| Range | 0-269 | |
| Median WBC, × 109/L | 8.7 | |
| Range | 1.1-89 | |
| Median hemoglobin, g/dL | 9.8 | |
| Range | 7.8-17.3 | |
| Median platelets, × 109/L | 137 | |
| Range | 8-1,183 | |
| Previously treated | 30 | 75 |
| No. of prior therapies | 1 | |
| Range | 1-4 | |
| Hydroxyurea | 14 | 35 |
| Azacitidine | 6 | 15 |
| Corticosteroids | 5 | 12.5 |
| Anagrelide | 4 | 10 |
| Thalidomide | 4 | 10 |
| Interferon-α | 3 | 7.5 |
| Previously untreated | 10 | 25 |
| JAK2V617F mutation* | 20/36 | 56 |
| Abnormal cytogenetics | 18/36 | 50 |
Abbreviation: WBC, white blood cell.
*
Assessed in bone marrow by a quantitative pyrosequencing assay.